Covid 19 Research using Clinical Trials (Home Page)
Non Extracorporeal Membrane OxygenationWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
There is one clinical trial.
Clinical Trials
1 Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure
A highly pathogenic human coronavirus causing respiratory disease emerged in Saudi Arabia in 2012. This viral infection termed Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with high mortality rate in approximately 36% of reported patients. The World Health Organization (WHO) reported 1,374 laboratory-confirmed worldwide infections, including at least 490 related deaths, from September, 2012, to July 24, 2015.2 The higher incidence of MERS-CoV infections in Saudi Arabia may be related to multiple factors, including seasonality, increased proactive screening, poor infection control measures, low relative humidity, and high temperature. Infected patients with MERS-CoV usually have abnormal findings on chest radiography, ranging from subtle to extensive unilateral and bilateral abnormalities. MERS progresses rapidly to respiratory failure, in approximately 2/3 of infected patients, which has a high mortality rate, particularly in immunocompromised patients. Extracorporeal membrane oxygenation (ECMO) has emerged as a rescue therapy in patients with refractory hypoxemia during the H1N1 epidemic.The use of veno-venous (VV)-ECMO provides respiratory support for patients with respiratory failure, whereas the use of veno-arterial (VA)-ECMO could be helpful in those with cardiorespiratory failure.10 However, the survival rate of the infected patients with H1N1 who required the use of ECMO varies considerably among the Caucasian and Asian countries (90% survival in Sweden and 83% in the UK13 vs. 35% in Japan). This large discrepancy could be explained with lack of satisfactory equipment, therapeutic guidelines, training of staff, and effective systems allowing patient transfer to the dedicated ECMO centres. Guery and co-investigators described the use of ECMO in two French patients with cardiorespiratory failure secondary to MERS-CoV infection.This has been extended for treatment of refractory hypoxemic respiratory failure during the Saudi MERS-CoV outbreak.
NCT02627378 MERS-CoV Infection Refractory Hypoxemia Other: Extracorporeal Membrane Oxygenation Other: Non Extracorporeal Membrane Oxygenation MeSH:Hypoxia
HPO:Hypoxemia
Primary Outcomes
Description: In-hospital mortality
Measure: Mortality rate Time: For 2 months after admission to hospital
Secondary Outcomes
Description: Use of ribavirin or other anti-viral medications
Measure: Use of antiviral medications Time: For 2 months after admission to hospital
Measure: Use of steroid medications Time: For 2 months after admission to hospital
Measure: Use of interferons Time: For 2 months after admission to hospital
Measure: Use of immunoglobulin Time: For 2 months after admission to hospital
Description: Use of norepinephrine or vasopressin
Measure: Use of vasopressor medications Time: For 2 months after admission to hospital
Description: Use of dobutamine, epinephrine, milirinone, levosimendan
Measure: Use of inotropic medications Time: For 2 months after admission to hospital
Measure: Need for renal replacement therapy Time: For 2 months after admission to hospital
Description: Changes in white and red blood cells and platelets counts
Measure: Changes in blood cell count Time: For 2 months after admission to hospital
Description: Changes in serum creatinine and blood urea nitrogen evels
Measure: Changes in renal function tests Time: For 2 months after admission to hospital
Description: Changes in arterial blood gases variables
Measure: Changes in arterial blood gases levels Time: For 2 months after admission to hospital
Measure: Ratio of arterial oxygen tension (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2/FiO2 ratio) Time: For 2 months after admission to hospital
Measure: Use of alveolar recruitment technique Time: For 2 months after admission to hospital
Measure: Use of prone ventilation Time: For 2 months after admission to hospital
Measure: Use of neuromuscular blockades Time: For 2 months after admission to hospital
Measure: Bacterial co-infection Time: For 2 months after admission to hospital
Measure: Hospital length of stay Time: For 2 months after admission to hospital
Measure: ICU length of stay Time: For 2 months after admission to hospital
Measure: Extracorporeal membrane oxygenation support gas flow (liter/min) Time: For 2 months after admission to hospital
Measure: Extracorporeal membrane oxygenation support blood flow (liter/min/m2) Time: For 2 months after admission to hospital
Measure: Duration of Extracorporeal membrane oxygenation circulatory support Time: For 2 months after admission to hospital
Other Outcomes
Measure: Number of participants with diabetes milletus on blood glucose test Time: For 1 month before admission to hospital
Measure: Number of participants with pregnancy on pregnancy test Time: For 9 months before admission to hospital
Measure: Number of participants with hypertension on blood pressure recordings Time: For 1 month before admission to hospital
Measure: Number of participants with acute kidney injury on renal function tests Time: For 1 month before admission to hospital
Measure: Number of participants with coronary artery disease on history, elctrocardiography and echocardiography Time: For 1 month before admission to hospital
Measure: Number of participants with congestive heart failure on echocardiography Time: For 1 month before admission to hospital
Measure: Number of participants with chronic kidney disease on renal function tests Time: For 1 month before admission to hospital
Measure: Number of participants with liver cell disease on liver function tests Time: For 1 month before admission to hospital
Measure: Number of participants with bronchial asthma on history and clinical examination Time: For 1 month before admission to hospital
Measure: Number of participants with chronic obstructive pulmonary disease on history, chest radiography and pulmonary function tests Time: For 1 month before admission to hospital
Measure: The presence of a predefined immunosuppression disease Time: For 1 month before admission to hospital
Related HPO nodes (Using clinical trials)
Primary Outcomes
Description: In-hospital mortality
Measure: Mortality rate Time: For 2 months after admission to hospitalSecondary Outcomes
Description: Use of ribavirin or other anti-viral medications
Measure: Use of antiviral medications Time: For 2 months after admission to hospitalMeasure: Use of steroid medications Time: For 2 months after admission to hospital
Measure: Use of interferons Time: For 2 months after admission to hospital
Measure: Use of immunoglobulin Time: For 2 months after admission to hospital
Description: Use of norepinephrine or vasopressin
Measure: Use of vasopressor medications Time: For 2 months after admission to hospitalDescription: Use of dobutamine, epinephrine, milirinone, levosimendan
Measure: Use of inotropic medications Time: For 2 months after admission to hospitalMeasure: Need for renal replacement therapy Time: For 2 months after admission to hospital
Description: Changes in white and red blood cells and platelets counts
Measure: Changes in blood cell count Time: For 2 months after admission to hospitalDescription: Changes in serum creatinine and blood urea nitrogen evels
Measure: Changes in renal function tests Time: For 2 months after admission to hospitalDescription: Changes in arterial blood gases variables
Measure: Changes in arterial blood gases levels Time: For 2 months after admission to hospitalMeasure: Ratio of arterial oxygen tension (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2/FiO2 ratio) Time: For 2 months after admission to hospital
Measure: Use of alveolar recruitment technique Time: For 2 months after admission to hospital
Measure: Use of prone ventilation Time: For 2 months after admission to hospital
Measure: Use of neuromuscular blockades Time: For 2 months after admission to hospital
Measure: Bacterial co-infection Time: For 2 months after admission to hospital
Measure: Hospital length of stay Time: For 2 months after admission to hospital
Measure: ICU length of stay Time: For 2 months after admission to hospital
Measure: Extracorporeal membrane oxygenation support gas flow (liter/min) Time: For 2 months after admission to hospital
Measure: Extracorporeal membrane oxygenation support blood flow (liter/min/m2) Time: For 2 months after admission to hospital
Measure: Duration of Extracorporeal membrane oxygenation circulatory support Time: For 2 months after admission to hospital
Other Outcomes
Measure: Number of participants with diabetes milletus on blood glucose test Time: For 1 month before admission to hospitalMeasure: Number of participants with pregnancy on pregnancy test Time: For 9 months before admission to hospital
Measure: Number of participants with hypertension on blood pressure recordings Time: For 1 month before admission to hospital
Measure: Number of participants with acute kidney injury on renal function tests Time: For 1 month before admission to hospital
Measure: Number of participants with coronary artery disease on history, elctrocardiography and echocardiography Time: For 1 month before admission to hospital
Measure: Number of participants with congestive heart failure on echocardiography Time: For 1 month before admission to hospital
Measure: Number of participants with chronic kidney disease on renal function tests Time: For 1 month before admission to hospital
Measure: Number of participants with liver cell disease on liver function tests Time: For 1 month before admission to hospital
Measure: Number of participants with bronchial asthma on history and clinical examination Time: For 1 month before admission to hospital
Measure: Number of participants with chronic obstructive pulmonary disease on history, chest radiography and pulmonary function tests Time: For 1 month before admission to hospital
Measure: The presence of a predefined immunosuppression disease Time: For 1 month before admission to hospital